Manufacturing · Profile from Manufacturing Research Companion: Companies, Strategic Moves, and Technical Studies
Baxter International
The Deerfield, Illinois maker of intravenous (IV) solutions, infusion systems, injectable drugs and hospital products that pioneered commercially made IV fluids in the 1930s. For decades it has been one of the largest US suppliers of a product hospitals cannot do without and that earns almost nothing per bag. Baxter's manufacturing story turns on single-site concentration in an essential product, and process capability treated as public infrastructure. In 2008 a contaminated heparin ingredient from a Chinese supplier reached patients through Baxter's vials. Over 2013–25 Baxter bought and sold whole businesses: Gambro in, Baxalta out, Hillrom in, Kidney Care out. In late September 2024 Hurricane Helene flooded its North Cove plant in Marion, North Carolina, which made ~60% of US IV-solution production (reported), and the country rationed IV fluids for months. The North Cove story is the clearest case in this knowledge base of a plant that is, in effect, part of the national health system while being run as one line in a public company's cost base.
At a glance
- Founded
- 1931, as Don Baxter Intravenous Products, by Dr. Donald Baxter with Dr. Ralph Falk as backer and later leader (from memory, verify); first plant in Glenview, Illinois (from memory, verify)
- Headquarters
- Deerfield, Illinois
- Ownership / structure
- Public (NYSE: BAX)
- Leadership (2026)
- Andrew Hider, president and CEO (named in 2025, start month from memory — verify; he led Baxter's Q3 2025 and Q3 2026 results)
- Segments (2026)
- Medical Products & Therapies (IV solutions, infusion pumps, administration sets, surgical products and the former Hillrom hospital products); Pharmaceuticals (injectables, anaesthesia, drug compounding); Healthcare Systems & Technologies (Hillrom care and connected-care products) — segment names after the Kidney Care sale (company, verify exact labels)
- Scale
- Q3 2026 (release 29 Oct 2026): sales ~$2.98bn (+5% reported and organic); Medical Products & Therapies ~$2.1bn (+6%); US ~$1.6bn (+3%); GAAP diluted EPS $0.57, adjusted $0.58; free cash flow $448m in the quarter and $705m year to date; a $600m cash debt tender completed; full-year 2026 outlook raised (company release, reported)
- Plants (US, selected)
- North Cove, Marion, North Carolina (IV solutions and peritoneal-dialysis fluids; flooded Sep 2024); Hillrom's former sites (Batesville, Indiana, and others — from memory, verify); international IV-solution plants in Europe, Latin America and Asia used as surge supply in 2024 (reported)
- Signature moves (incl. failures)
- IV solutions and the first commercial IV containers (1931–); the heparin contamination (2008); Gambro (2013); the Baxalta spin-off (2015); the foreign-exchange accounting investigation and SEC settlement (2019–22); Hillrom (2021, ~$12.5bn EV); North Cove and Hurricane Helene (2024–25); the Vantive Kidney Care sale to Carlyle (2025)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1931
Founding and Commercial IV Solutions
Founding / product and process launch (factory-made sterile IV solutions)
2008
Heparin Contamination
Quality failure and recall — a supplier's adulterated active ingredient reached patients in Baxter's finished heparin
2013
Gambro Acquisition
Acquisition (renal-care scale: haemodialysis machines and dialyzers added to Baxter's peritoneal dialysis)
2015
Baxalta Spin Off
Spin-off (BioScience — plasma-derived and recombinant therapies — separated as Baxalta)
2019
FX Accounting Investigation and SEC Settlement
Regulatory and legal action (accounting misstatement, internal investigation, SEC settlement) — a failure
2021
Hillrom Acquisition
Acquisition (debt-financed; hospital beds, patient monitoring, care communications and front-line diagnostics)
2024
North Cove and Hurricane Helene
Natural disaster at a single site / disruption and recovery (a failure of resilience, followed by a competent restart)
2025
Vantive Kidney Care Sale to Carlyle
Divestment to private equity (carve-out of Kidney Care, renamed Vantive)